Inclusion Criteria:

- Adenocarcinoma of the prostate with radiographic evidence of metastatic disease.

- Willingness to undergo a baseline tumor biopsy.

- Castrate levels of testosterone (testosterone < 50 ng/dL) on androgen deprivation
therapy (ADT) with evidence of progression on ADT. GnRH therapy will be continued
for those on it at baseline

- Patient must have suspected tumor in an area that is safe to biopsy.

- Other prior hormonal interventions or experimental approaches are allowed. These
therapies must have been discontinued for a minimum of 28 days with cancer
progression.

- Prior or concurrent use of bisphosphonates is allowed.

- One prior non-taxane chemotherapy allowed

- ≥ 3 weeks since major surgery; ≥ 4 weeks since radiotherapy; ≥ 8 weeks since prior
strontium-89 or samarium 153

- Performance Status: ECOG 0 or 1

- ANC > 1,500/_l; platelets > 100,000/_l; total Bilirubin < upper limit of normal; AST
and ALT < 3 x upper limits of normal; creatinine < 1.5 x upper limits of normal;
total fasting cholesterol < 350 mg/dl; total triglycerides < 300 mg/dl

Exclusion Criteria:

- Ongoing oral steroid use. Patients with a history of oral steroid use are eligible
as long as the steroids have been discontinued prior to study entry. Ongoing topical
and/or inhaled steroid use is allowed.

- Prior taxane chemotherapy

- Prior mTOR inhibitors (RAD001, rapamycin, CCI-779)

- Currently active second malignancy other than non-melanoma skin cancer.

- Ongoing peripheral neuropathy of Grade 2